Last reviewed 2026-04-19 · How we verify

SYO-1126

Samyang Biopharmaceuticals Corporation · Phase 1 active Small molecule

SYO-1126 is a Small molecule drug developed by Samyang Biopharmaceuticals Corporation. It is currently in Phase 1 development. Also known as: Imatinib 400mg.

At a glance

Generic name	SYO-1126
Also known as	Imatinib 400mg
Sponsor	Samyang Biopharmaceuticals Corporation
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Crossover Study to Compare Pharmacokinetic Property of SYO-1126 and Glivec Film Coated Tab in Healthy Male Volunteers (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

SYO-1126 CI brief — competitive landscape report
SYO-1126 updates RSS · CI watch RSS
Samyang Biopharmaceuticals Corporation portfolio CI

Frequently asked questions about SYO-1126

What is SYO-1126?

SYO-1126 is a Small molecule drug developed by Samyang Biopharmaceuticals Corporation.

Who makes SYO-1126?

SYO-1126 is developed by Samyang Biopharmaceuticals Corporation (see full Samyang Biopharmaceuticals Corporation pipeline at /company/samyang-biopharmaceuticals-corporation).

Is SYO-1126 also known as anything else?

SYO-1126 is also known as Imatinib 400mg.

What development phase is SYO-1126 in?

SYO-1126 is in Phase 1.

Manufacturer: Samyang Biopharmaceuticals Corporation — full pipeline
Also known as: Imatinib 400mg
Compare: SYO-1126 vs similar drugs
Pricing: SYO-1126 cost, discount & access